The pentavalent reconstituted live attenuated rotavirus vaccine (RV5) is currently classified as a Class II vaccine, i.e. a non-immunization programmed vaccine, and is administered voluntarily and at one’s own expense.
Rotavirus gastroenteritis (RVGE) is the most common type of viral gastroenteritis and is mainly caused by group A rotavirus (RV) infection. Rotaviruses are fairly stable in the external environment, have a low infectious dose, and are highly resistant, so they are susceptible to larger-scale infections in the fall and winter and even at various times throughout the year.
The first dose is given at 6-12 weeks of age (42-90 d) after birth, with an interval of ≥4 weeks between doses and a third dose no later than 32 weeks of age (230 d).
Common adverse reactions include fever, diarrhea, vomiting, and occasionally cough, gastroenteritis, pharyngitis, upper respiratory tract infection, flatulence, food reflux, and crying. They usually last for a few days and resolve on their own. If symptoms persist, prompt hospitalization is required.